Hikma Eyes Another Hybrid Injectable With Arecor
Second Agreement Using 505(b)(2) Pathway
London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
Hikma has struck a deal to develop with the UK’s Arecor a ready-to-use injectable that will be filed under the US 505(b)(2) hybrid regulatory pathway.